Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Butobarbital is a sedative and a hypnotic drug.
- Mechanism
- Curator reviewed
Butethal binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
- Primary indication
- For the treatment of insomnia.Curator reviewed
- Formula / weight
- C10H16N2O3 · 212.2456 g/mol (avg)
- Also known as
- Butethal · Butobarbitone
Resolves to
STDBAQMTJLUMFW-UHFFFAOYSA-NSMILESCCCCC1(CC)C(=O)NC(=O)NC1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Butobarbital, and which of those have an active Phase 3 trial?